GD2-targeted immunotherapy for neuroblastoma — the monoclonal antibody and CAR-T cell therapies targeting the disialoganglioside GD2 antigen uniformly expressed on neuroblastoma cells, transforming high-risk disease outcomes from <50% to >70% long-term survival representing the fastest-growing therapeutic paradigm in the global neuroblastoma cancer market — creates the most...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)